SCHEMBL21392464

SCHEMBL21392464

CC(C)(C)c1ccc(N2c3ccccc3Oc3c(-c4ccccn4)cccc32)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.37
BCR P11274 1/20 0.37
AKT1 P31749 2/20 0.36
AKT2 P31751 1/20 0.35
AKT3 Q9Y243 1/20 0.35
TRPV1 Q8NER1 1/20 0.35
ALDH1A1 P00352 4/20 0.35
MAPT P10636 3/20 0.35
NPSR1 Q6W5P4 3/20 0.35
RAB9A P51151 2/20 0.35
POLB P06746 1/20 0.35
HPGD P15428 1/20 0.35
HSD17B10 Q99714 1/20 0.35
HTR7 P34969 1/20 0.34
METAP2 P50579 1/20 0.34
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
LMNA P02545 1/20 0.32
TSHR P16473 1/20 0.32
MAPK1 P28482 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21392302 0.81 ABL1 (0.43) ABL1BCRAKT1TRPV1ALDH1A1
SCHEMBL14932219 0.78 P2RX4 (0.38) TRPV1ALDH1A1MAPTNPSR1LMNA
SCHEMBL21381185 0.78 P2RX4 (0.33) ALDH1A1NPSR1NR1H2NR1H3
SCHEMBL19794965 0.77 HTR7 (0.40) ALDH1A1MAPTRAB9APOLBHPGD
SCHEMBL17948187 0.74 CCR1 (0.42) ABL1BCRTRPV1ALDH1A1MAPT
SCHEMBL17948183 0.74 CCR1 (0.42) ABL1BCRTRPV1ALDH1A1MAPT
SCHEMBL13308158 0.73 EGLN1 (0.40) MAPTNPSR1RAB9APOLBKMT2A
SCHEMBL17948180 0.73 SMN1; SMN2 (0.40) ABL1BCRTRPV1ALDH1A1MAPT
SCHEMBL17489943 0.73 PDK2 (0.38) HTR7
SCHEMBL21392426 0.72 JAK2 (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10886477-B2 Iridium complex and organic electroluminescence device using the same UDC IRELAND LIMITED (IE) 2021-01-05 US disclosed
US-20190296251-A1 IRIDIUM COMPLEX AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME LUMINESCENCE TECHNOLOGY CORPORATION (TW) 2019-09-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190296251-A1 IRIDIUM COMPLEX AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME IMPA1, LAGE3, OCIAD1 ABL1 1855/4885BCR 3443/4885AKT1 2935/4885
US-10886477-B2 Iridium complex and organic electroluminescence device using the same IMPA1, LAGE3, OCIAD1 ABL1 1855/4885BCR 3443/4885AKT1 2935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.